ClinicalTrials.gg
CompletedNCT07786740Updated Aug 26, 2026

VIMA vs TIVA and ONSD in Laparoscopic Cholecystectomy

A Phase 4 interventional study of Propofol (Astra-Zeneca) and Remifentanil in Intracranial Pressure Change and Optic Nerve Diameter, sponsored by Bagcilar Training and Research Hospital. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by Bagcilar Training and Research Hospital · Phase 4, Interventional, and Other

From the registry’s dates

  • Registered 3 years 7 months after the study started (first participant enrolled Jan 2023, registered Aug 2026).
Phase
Phase 4
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study compared two commonly used general anesthesia techniques in adults undergoing elective laparoscopic gallbladder surgery. One group received total intravenous anesthesia (TIVA) with propofol, while the other group received volatile induction and maintenance anesthesia (VIMA) with sevoflurane.

The main purpose of the study was to compare changes in optic nerve sheath diameter, measured noninvasively by ultrasound, because this measurement can reflect changes in pressure inside the skull. Measurements were taken at several time points before, during, and after surgery. The study also compared blood pressure, heart rate, oxygen levels, depth of anesthesia, breathing-related measurements, postoperative pain, nausea, vomiting, headache, recovery time, and anesthetic drug cost between the two groups.

Adult patients aged 18 to 80 years with ASA physical status I-II who were scheduled for elective laparoscopic cholecystectomy were included. The study was conducted at Istanbul Bağcılar Training and Research Hospital.

Read the detailed description

This prospective, single-center, randomized, open-label study compared total intravenous anesthesia (TIVA) with volatile induction and maintenance anesthesia (VIMA) in adult patients undergoing elective laparoscopic cholecystectomy. The primary objective was to evaluate whether the anesthetic technique influenced perioperative changes in optic nerve sheath diameter (ONSD), a noninvasive ultrasonographic surrogate marker of intracranial pressure.

ONSD was measured from the right eye using a 12-MHz linear ultrasound probe at six predefined perioperative time points: before induction, after tracheal intubation, after pneumoperitoneum, after reverse Trendelenburg positioning, 30 minutes after intubation, and after desufflation. Six consecutive measurements were obtained at each time point and averaged. Pneumoperitoneum pressure was maintained at 12 mmHg, reverse Trendelenburg positioning was 15°-30°, and anesthetic depth was guided by Bispectral Index monitoring.

Secondary assessments included intraoperative hemodynamic and respiratory variables, postoperative pain, nausea, vomiting, headache, diplopia, recovery time, and anesthetic drug cost. The final analysis was performed on the evaluable per-protocol population.

02

Conditions studied

  • Intracranial Pressure Change
  • Optic Nerve Diameter

Browse trials for

Keywords

  • optic nerve sheath diameter
  • total intravenous anesthesia
  • sevoflurane
  • propofol
  • laparoscopic cholecystectomy
  • pneumoperitoneum
  • intracranial pressure
03

In context

Pneumoperitoneum

134 studies on the registry are indexed under Pneumoperitoneum; 28 are open to participants now.

This study's enrollment of 80 is close to the median of 76 across 77 interventional studies indexed under Pneumoperitoneum.

Browse Pneumoperitoneum studies →

Lead sponsor

Bagcilar Training and Research Hospital is the lead sponsor of 55 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-80 years
  • (ASA) physical status I-II
  • Scheduled for elective laparoscopic cholecystectomy
  • Provided written to participate

Exclusion criteria

Exclusion Criteria:

  • Refusal to participate
  • Uncontrolled hypertension
  • Uncontrolled diabetes mellitus
  • History of
  • Severe cardiovascular disease, including congestive heart failure or myocardial infarction
  • Severe cerebrovascular disease, including previous stroke
  • Hepatic dysfunction
  • Renal dysfunction
  • Pregnancy or lactation
  • Intracranial space-occupying lesion or any condition predisposing to increased intracranial pressure
  • Known optic nerve pathology
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Total Intravenous Anesthesia (TIVA)

    Anesthesia was induced with intravenous propofol 2-2.5 mg/kg and fentanyl 2 µg/kg, with rocuronium 0.6 mg/kg for neuromuscular blockade. Anesthesia was maintained with propofol infusion (75-250 µg/kg/min) and remifentanil infusion (0.1 µg/kg/min), titrated to maintain a Bispectral Index of 40-60.

    Drug: Propofol (Astra-Zeneca) · Drug: Remifentanil

  • Active comparator
    Volatile Induction and Maintenance Anesthesia (VIMA)

    Anesthesia was induced with 8% sevoflurane in a 50% oxygen/50% air mixture at a fresh gas flow of 6 L/min. Fentanyl 2 µg/kg and rocuronium 0.6 mg/kg were administered, followed by endotracheal intubation. Anesthesia was maintained with sevoflurane 2.5-3.3%, titrated to maintain a Bispectral Index of 40-60.

    Drug: Sevofluorane

Interventions

  • Propofol was administered intravenously at 2-2.5 mg/kg for induction of anesthesia and was continued as an infusion at 75-250 µg/kg/min for maintenance, titrated to maintain a Bispectral Index of 40-60.

  • Remifentanil was administered as a continuous intravenous infusion at 0.1 µg/kg/min during maintenance of anesthesia in the TIVA group.

  • Sevoflurane was administered at 8% in a 50% oxygen/50% air mixture with a fresh gas flow of 6 L/min for inhalational induction. Anesthesia was maintained with sevoflurane at 2.5-3.3%, titrated to maintain a Bispectral Index of 40-60.

06

What researchers measure

Primary outcomes

  1. Change in Optic Nerve Sheath Diameter During the Perioperative Period

    Optic nerve sheath diameter (ONSD) was measured ultrasonographically in the right eye using a 12-MHz linear probe, 3 mm posterior to the point at which the optic nerve enters the globe. Six consecutive measurements were obtained at each time point and averaged. The perioperative ONSD profile was compared between the TIVA and VIMA groups.

    Time frame: From before induction of anesthesia to 5 minutes after desufflation

Secondary outcomes

  1. Systolic Arterial Pressure

    Systolic arterial pressure were recorded and compared between the TIVA and VIMA groups.

    Time frame: From before induction of anesthesia to 5 minutes after desufflation

  2. Change in Peripheral Oxygen Saturation

    Peripheral oxygen saturation (SpO₂) was recorded and compared between groups

    Time frame: From before induction of anesthesia to 5 minutes after desufflation

  3. Change in Bispectral Index

    Bispectral Index (BIS) values were recorded to assess anesthetic depth and compared between groups

    Time frame: From before induction of anesthesia to 5 minutes after desufflation

  4. Anesthetic Drug Cost

    Total intraoperative consumption of propofol and remifentanil in the TIVA group and sevoflurane in the VIMA group was recorded, and anesthetic drug cost was calculated in Turkish Lira using the 2023 hospital acquisition price list.

    Time frame: From induction of anesthesia to completion of anesthesia

  5. Diastolic Arterial Pressure

    Diastolic arterial pressure was recorded in millimeters of mercury (mmHg) at T0, T1, T2, T3, T4, and T5.

    Time frame: From before induction of anesthesia to 5 minutes after desufflation

  6. Mean Arterial Pressure

    Mean arterial pressure was recorded in millimeters of mercury (mmHg) at T0, T1, T2, T3, T4, and T5.

    Time frame: From before induction of anesthesia to 5 minutes after desufflation

  7. Heart Rate

    Heart rate was recorded in beats per minute at T0, T1, T2, T3, T4, and T5.

    Time frame: From before induction of anesthesia to 5 minutes after desufflation

07

Study locations

1 site
  • Isntabul Bagcilar Research and Training Hospital
    Istanbul, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared because no prospective data-sharing plan or consent for external sharing of individual-level data was established for this study.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07786740
Lead sponsor
Bagcilar Training and Research Hospital
Responsible party
Serdar Demirgan (Associate proffesor, Bagcilar Training and Research Hospital) — Principal investigator
First posted
Aug 26, 2026
Start date
Jan 1, 2023
Primary completion
May 1, 2023
Completion
May 5, 2023
Last update
Aug 26, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Propofol · Remifentanil

Start the discussion